 <h1>Panobinostat Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of panobinostat include:</b> severe diarrhea, pneumonia, severe infection, severe neutropenia, cardiac arrhythmia, abnormal t waves on ecg, depression of st segment on ecg, diarrhea, neutropenia, and thrombocytopenia. <b>Other side effects include:</b> sepsis, and hemorrhage.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to panobinostat: oral capsule</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Capsule)</p><p>Severe diarrhea has been reported with panobinostat. Monitor for diarrhea, institute antidiarrheal treatment, interrupt therapy, then reduce the dose or discontinue panobinostat if necessary for severe diarrhea. Severe and fatal cardiac ischemic events, severe arrhythmias, and ECG changes have occurred in patients receiving panobinostat, and electrolyte abnormalities may exacerbate arrhythmias. A baseline ECG and electrolyte panel is recommended, along with periodic monitoring during treatment as clinically indicated.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, panobinostat may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking panobinostat:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain or tenderness</li>
<li>black, tarry stools</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>clay colored stools</li>
<li>confusion</li>
<li>cough or sore throat</li>
<li>dark or bloody urine</li>
<li>decreased appetite</li>
<li>decreased frequency or amount of urine</li>
<li>dizziness, faintness, or lightheadedness especially when getting up suddenly from a lying or sitting position</li>
<li>fast, irregular, pounding, or racing heartbeat or pulse</li>
<li>fever, chills, or sweating</li>
<li>headache</li>
<li>increased thirst</li>
<li>itching or skin rash</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>muscle spasms or twitching</li>
<li>nausea or vomiting</li>
<li>nervousness</li>
<li>painful or difficult urination</li>
<li>pinpoint red spots on the skin</li>
<li>pounding in the ears</li>
<li>rapid breathing</li>
<li>seizures</li>
<li>severe diarrhea</li>
<li>slow or fast heartbeat</li>
<li>swelling of the face, fingers, feet, or lower legs</li>
<li>tingling of the hands or feet</li>
<li>trouble breathing</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest pain or discomfort</li>
<li>coughing up blood</li>
<li>difficulty with swallowing</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>nosebleeds</li>
<li>pain in the shoulders, arms, jaw, or neck</li>
<li>paralysis</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of panobinostat may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching or passing gas</li>
<li>change or loss in taste</li>
<li>depressed mood</li>
<li>dry mouth</li>
<li>hair loss</li>
<li>heartburn or indigestion</li>
<li>hoarseness or husky voice</li>
<li>fatigue or feeling lethargic</li>
<li>redness of the skin</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to panobinostat: oral capsule</i></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (68%), nausea (36%), vomiting (26%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, dyspepsia, gastritis, cheilitis, abdominal distension, dry mouth, flatulence, colitis, gastrointestinal pain</p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): T-wave abnormalities (40%), ST-segment depression (22%), arrhythmia (12%)</p>
<p><b>Common</b> (1% to 10%): Palpitations, hypotension, hypertension, orthostatic hypotension</p>
<p><b>Uncommon</b> (0.1% to 1%): Cardiac ischemic events<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Thrombocytopenia (97%), lymphopenia (82%), leukopenia (81%), neutropenia (75%), anemia (62%)</p>
<p><b>Common</b> (1% to 10%): Grade 3/4 hemorrhage</p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Severe infections (31%)</p>
<p><b>Common</b> (1% to 10%): Hepatitis B</p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased blood alkaline phosphatase </p>
<p><b>Frequency not reported</b>: Hepatic dysfunction (primarily aminotransferase and total bilirubin elevations)</p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypocalcemia (67%), hypoalbuminemia (63%), hypophosphatemia (63%), hypokalemia (52%), hyponatremia (49%), hyperphosphatemia (29%), decreased appetite (28%), hypermagnesemia (27%), hyperbilirubinemia (21%), decreased weight (12%)</p>
<p><b>Common</b> (1% to 10%): Hyperglycemia, dehydration, fluid retention, hypomagnesemia</p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Skin lesions, rash, erythema</p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Hypothyroidism</p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary incontinence, hyperuricemia</p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Joint swelling</p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, headache, syncope, tremor, dysgeusia</p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (60%), peripheral edema (29%), pyrexia (26%)</p>
<p><b>Common</b> (1% to 10%): Chills</p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased blood creatinine (41%)</p>
<p><b>Common</b> (1% to 10%): Renal failure, increased blood urea, decreased glomerular filtration rate</p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough, dyspnea, respiratory failure, rales, wheezing</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Farydak (panobinostat)." Novartis Pharmaceuticals, East Hanover, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about panobinostat</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: histone deacetylase inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Panobinostat &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Farydak</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Myeloma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to panobinostat: oral capsule</i></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (68%), nausea (36%), vomiting (26%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, dyspepsia, gastritis, cheilitis, abdominal distension, dry mouth, flatulence, colitis, gastrointestinal pain</p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): T-wave abnormalities (40%), ST-segment depression (22%), arrhythmia (12%)</p><p><b>Common</b> (1% to 10%): Palpitations, hypotension, hypertension, orthostatic hypotension</p><p><b>Uncommon</b> (0.1% to 1%): Cardiac ischemic events<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Thrombocytopenia (97%), lymphopenia (82%), leukopenia (81%), neutropenia (75%), anemia (62%)</p><p><b>Common</b> (1% to 10%): Grade 3/4 hemorrhage</p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Severe infections (31%)</p><p><b>Common</b> (1% to 10%): Hepatitis B</p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased blood alkaline phosphatase </p><p><b>Frequency not reported</b>: Hepatic dysfunction (primarily aminotransferase and total bilirubin elevations)</p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypocalcemia (67%), hypoalbuminemia (63%), hypophosphatemia (63%), hypokalemia (52%), hyponatremia (49%), hyperphosphatemia (29%), decreased appetite (28%), hypermagnesemia (27%), hyperbilirubinemia (21%), decreased weight (12%)</p><p><b>Common</b> (1% to 10%): Hyperglycemia, dehydration, fluid retention, hypomagnesemia</p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Skin lesions, rash, erythema</p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Hypothyroidism</p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary incontinence, hyperuricemia</p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Joint swelling</p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, headache, syncope, tremor, dysgeusia</p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (60%), peripheral edema (29%), pyrexia (26%)</p><p><b>Common</b> (1% to 10%): Chills</p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased blood creatinine (41%)</p><p><b>Common</b> (1% to 10%): Renal failure, increased blood urea, decreased glomerular filtration rate</p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough, dyspnea, respiratory failure, rales, wheezing</p><p id="ref_1">1. "Product Information. Farydak (panobinostat)." Novartis Pharmaceuticals, East Hanover, NJ. </p><h2>More about panobinostat</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: histone deacetylase inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Panobinostat &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Myeloma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>